Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: Open-label continuation study

William R. Lumry, Jonathan A. Bernstein, H. Henry Li, Andrew J. MacGinnitie, Marc Riedl, Daniel F. Soteres, Timothy Craig, Marilyn Campion, Ryan Iarrobino, Leslie E. Stolz, William E. Pullman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hereditary angioedema (HAE) is a rare disorder characterized by recurrent attacks of potentially life-threatening edema. The plasma kallikrein inhibitor ecallantide is approved for treatment of acute HAE attacks. This study evaluates the efficacy and safety of ecallantide for treatment of multiple HAE episodes in the DX-88/19 (continuation) study. Patients received 30 mg of subcutaneous ecallantide for acute HAE attack symptoms, with no limit on number of episodes treated. Primary end point was change in patient-reported mean symptom complex severity (MSCS) score at 4 hours. Additional end points included change in MSCS score at 24 hours, treatment outcome score (TOS) at 4 and 24 hours, and time to response. Safety parameters included adverse events. Statistical analyses were conducted on qualifying treatment episodes (those with ≥12 patients). One hundred forty-seven patients received treatment for 625 episodes; analyses were conducted through 13 treatment episodes. Across 13 episodes at 4 hours, mean change in MSCS score ranged from -1.04 to -1.36, and mean TOSs ranged from 56.2 to 79.8. Median time to onset of sustained improvement ranged from 59 to 113 minutes. There was no indication of reduced efficacy with repeated ecallantide use. No new safety signals were detected. Eight patients (5.4%) reported potential hypersensitivity reactions, six of whom met the definition of anaphylaxis based on National Institute of Allergy and Infectious Diseases criteria. Ecallantide is effective for acute recurrent HAE attacks and maintains its efficacy and safety during multiple treatment episodes in patients with HAE. Potential hypersensitivity reactions were consistent with prior reports.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
JournalAllergy and Asthma Proceedings
Volume34
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Hereditary Angioedemas
Safety
Hypersensitivity
Therapeutics
National Institute of Allergy and Infectious Diseases (U.S.)
Plasma Kallikrein
Anaphylaxis
ecallantide
Edema

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Lumry, W. R., Bernstein, J. A., Li, H. H., MacGinnitie, A. J., Riedl, M., Soteres, D. F., ... Pullman, W. E. (2013). Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: Open-label continuation study. Allergy and Asthma Proceedings, 34(2), 155-161. https://doi.org/10.2500/aap.2013.34.3653
Lumry, William R. ; Bernstein, Jonathan A. ; Li, H. Henry ; MacGinnitie, Andrew J. ; Riedl, Marc ; Soteres, Daniel F. ; Craig, Timothy ; Campion, Marilyn ; Iarrobino, Ryan ; Stolz, Leslie E. ; Pullman, William E. / Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema : Open-label continuation study. In: Allergy and Asthma Proceedings. 2013 ; Vol. 34, No. 2. pp. 155-161.
@article{b508c4a08e8343d48bce4842007e21ad,
title = "Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: Open-label continuation study",
abstract = "Hereditary angioedema (HAE) is a rare disorder characterized by recurrent attacks of potentially life-threatening edema. The plasma kallikrein inhibitor ecallantide is approved for treatment of acute HAE attacks. This study evaluates the efficacy and safety of ecallantide for treatment of multiple HAE episodes in the DX-88/19 (continuation) study. Patients received 30 mg of subcutaneous ecallantide for acute HAE attack symptoms, with no limit on number of episodes treated. Primary end point was change in patient-reported mean symptom complex severity (MSCS) score at 4 hours. Additional end points included change in MSCS score at 24 hours, treatment outcome score (TOS) at 4 and 24 hours, and time to response. Safety parameters included adverse events. Statistical analyses were conducted on qualifying treatment episodes (those with ≥12 patients). One hundred forty-seven patients received treatment for 625 episodes; analyses were conducted through 13 treatment episodes. Across 13 episodes at 4 hours, mean change in MSCS score ranged from -1.04 to -1.36, and mean TOSs ranged from 56.2 to 79.8. Median time to onset of sustained improvement ranged from 59 to 113 minutes. There was no indication of reduced efficacy with repeated ecallantide use. No new safety signals were detected. Eight patients (5.4{\%}) reported potential hypersensitivity reactions, six of whom met the definition of anaphylaxis based on National Institute of Allergy and Infectious Diseases criteria. Ecallantide is effective for acute recurrent HAE attacks and maintains its efficacy and safety during multiple treatment episodes in patients with HAE. Potential hypersensitivity reactions were consistent with prior reports.",
author = "Lumry, {William R.} and Bernstein, {Jonathan A.} and Li, {H. Henry} and MacGinnitie, {Andrew J.} and Marc Riedl and Soteres, {Daniel F.} and Timothy Craig and Marilyn Campion and Ryan Iarrobino and Stolz, {Leslie E.} and Pullman, {William E.}",
year = "2013",
month = "1",
day = "1",
doi = "10.2500/aap.2013.34.3653",
language = "English (US)",
volume = "34",
pages = "155--161",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "2",

}

Lumry, WR, Bernstein, JA, Li, HH, MacGinnitie, AJ, Riedl, M, Soteres, DF, Craig, T, Campion, M, Iarrobino, R, Stolz, LE & Pullman, WE 2013, 'Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: Open-label continuation study', Allergy and Asthma Proceedings, vol. 34, no. 2, pp. 155-161. https://doi.org/10.2500/aap.2013.34.3653

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema : Open-label continuation study. / Lumry, William R.; Bernstein, Jonathan A.; Li, H. Henry; MacGinnitie, Andrew J.; Riedl, Marc; Soteres, Daniel F.; Craig, Timothy; Campion, Marilyn; Iarrobino, Ryan; Stolz, Leslie E.; Pullman, William E.

In: Allergy and Asthma Proceedings, Vol. 34, No. 2, 01.01.2013, p. 155-161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema

T2 - Open-label continuation study

AU - Lumry, William R.

AU - Bernstein, Jonathan A.

AU - Li, H. Henry

AU - MacGinnitie, Andrew J.

AU - Riedl, Marc

AU - Soteres, Daniel F.

AU - Craig, Timothy

AU - Campion, Marilyn

AU - Iarrobino, Ryan

AU - Stolz, Leslie E.

AU - Pullman, William E.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Hereditary angioedema (HAE) is a rare disorder characterized by recurrent attacks of potentially life-threatening edema. The plasma kallikrein inhibitor ecallantide is approved for treatment of acute HAE attacks. This study evaluates the efficacy and safety of ecallantide for treatment of multiple HAE episodes in the DX-88/19 (continuation) study. Patients received 30 mg of subcutaneous ecallantide for acute HAE attack symptoms, with no limit on number of episodes treated. Primary end point was change in patient-reported mean symptom complex severity (MSCS) score at 4 hours. Additional end points included change in MSCS score at 24 hours, treatment outcome score (TOS) at 4 and 24 hours, and time to response. Safety parameters included adverse events. Statistical analyses were conducted on qualifying treatment episodes (those with ≥12 patients). One hundred forty-seven patients received treatment for 625 episodes; analyses were conducted through 13 treatment episodes. Across 13 episodes at 4 hours, mean change in MSCS score ranged from -1.04 to -1.36, and mean TOSs ranged from 56.2 to 79.8. Median time to onset of sustained improvement ranged from 59 to 113 minutes. There was no indication of reduced efficacy with repeated ecallantide use. No new safety signals were detected. Eight patients (5.4%) reported potential hypersensitivity reactions, six of whom met the definition of anaphylaxis based on National Institute of Allergy and Infectious Diseases criteria. Ecallantide is effective for acute recurrent HAE attacks and maintains its efficacy and safety during multiple treatment episodes in patients with HAE. Potential hypersensitivity reactions were consistent with prior reports.

AB - Hereditary angioedema (HAE) is a rare disorder characterized by recurrent attacks of potentially life-threatening edema. The plasma kallikrein inhibitor ecallantide is approved for treatment of acute HAE attacks. This study evaluates the efficacy and safety of ecallantide for treatment of multiple HAE episodes in the DX-88/19 (continuation) study. Patients received 30 mg of subcutaneous ecallantide for acute HAE attack symptoms, with no limit on number of episodes treated. Primary end point was change in patient-reported mean symptom complex severity (MSCS) score at 4 hours. Additional end points included change in MSCS score at 24 hours, treatment outcome score (TOS) at 4 and 24 hours, and time to response. Safety parameters included adverse events. Statistical analyses were conducted on qualifying treatment episodes (those with ≥12 patients). One hundred forty-seven patients received treatment for 625 episodes; analyses were conducted through 13 treatment episodes. Across 13 episodes at 4 hours, mean change in MSCS score ranged from -1.04 to -1.36, and mean TOSs ranged from 56.2 to 79.8. Median time to onset of sustained improvement ranged from 59 to 113 minutes. There was no indication of reduced efficacy with repeated ecallantide use. No new safety signals were detected. Eight patients (5.4%) reported potential hypersensitivity reactions, six of whom met the definition of anaphylaxis based on National Institute of Allergy and Infectious Diseases criteria. Ecallantide is effective for acute recurrent HAE attacks and maintains its efficacy and safety during multiple treatment episodes in patients with HAE. Potential hypersensitivity reactions were consistent with prior reports.

UR - http://www.scopus.com/inward/record.url?scp=84876003802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876003802&partnerID=8YFLogxK

U2 - 10.2500/aap.2013.34.3653

DO - 10.2500/aap.2013.34.3653

M3 - Article

C2 - 23484891

AN - SCOPUS:84876003802

VL - 34

SP - 155

EP - 161

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 2

ER -